Lipoprotein particles and size, total and high molecular weight adiponectin, and leptin in relation to incident coronary heart disease among severely obese postmenopausal women: The Women's Health Initiative Observational Study

BBA Clinical

Volumn 3, Issue , 2015, Pages 243-250

  Mackey, Rachel H ^a   McTigue, Kathleen M ^a,b   Chang, Yuefang F ^b   Barinas Mitchell, Emma ^a   Evans, Rhobert W ^a   Tinker, Lesley F ^c   Lewis, Cora E ^d   Manson, JoAnn E ^e   Stefanick, Marcia L ^f   Howard, Barbara V ^g   Phillips, Lawrence S ^h,k   Liu, Simin ⁱ   Kulick, Doina ^j   Kuller, Lewis H ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MEDSTAR RESEARCH INSTITUTE   (United States)

^h ATLANTA VA MEDICAL CENTER   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j BROWN UNIVERSITY   (United States)

^k MAYO CLINIC   (United States)

more..

Author keywords

Adiponectin; Coronary heart disease; Extreme obesity; Lipoproteins; Postmenopausal women; Severe obesity

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN; LEPTIN; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; BODY MASS; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PARTICLE SIZE; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SMOKING; WAIST CIRCUMFERENCE;

EID: 84925066477     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2015.03.005     Document Type: Article

References (47)

1. Poirier P., Alpert M.A., Fleisher L.A., Thompson P.D., Sugerman H.J., Burke L.E., et al. Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association. Circulation 2009, 120(1):86-95.
2. Flegal K.M., Carroll M.D., Kit B.K., Ogden C.L. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012, 307(5):491-497.
3. McTigue K.M., Chang Y.F., Eaton C., Garcia L., Johnson K.C., Lewis C.E., et al. Severe obesity, heart disease, and death among white, African American, and Hispanic postmenopausal women. Obesity (Silver Spring) 2014, 22(3):801-810.
4. Sjostrom L., Peltonen M., Jacobson P., Sjostrom C.D., Karason K., Wedel H., et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012, 307(1):56-65.
5. McTigue K.M., Mackey R.H., Kuller L.H. Cardiovascular complications of extreme obesity in women. Curr. Cardiovasc. Risk Rep. 2011, 5:246-252.
6. Sattar N., Wannamethee G., Sarwar N., Chernova J., Lawlor D.A., Kelly A., et al. Leptin and coronary heart disease: prospective study and systematic review. J. Am. Coll. Cardiol. 2009, 53(2):167-175.
7. Sook Lee E., Park S.S., Kim E., Sook Yoon Y., Ahn H.Y., Park C.Y., et al. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int. J. Epidemiol. 2013, 42(4):1029-1039.
8. Lawlor D.A., Davey S.G., Ebrahim S., Thompson C., Sattar N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J. Clin. Endocrinol. Metab. 2005, 90(10):5677-5683.
9. Sattar N., Watt P., Cherry L., Ebrahim S., Davey S.G., Lawlor D.A. High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study. J. Clin. Endocrinol. Metab. 2008, 93(5):1846-1849.
10. Herder C., Peltonen M., Svensson P.A., Carstensen M., Jacobson P., Roden M., et al. Adiponectin and bariatric surgery: associations with diabetes and cardiovascular disease in the Swedish Obese Subjects Study. Diabetes Care 2014, 37(5):1401-1409.
11. Mackey R.H., Greenland P., Goff D.C., Lloyd-Jones D., Sibley C.T., Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 2012, 60(6):508-516.
12. Parish S., Offer A., Clarke R., Hopewell J.C., Hill M.R., Otvos J.D., et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 2012, 125(20):2469-2478.
13. Kuller L.H., Grandits G., Cohen J.D., Neaton J.D., Prineas R. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis 2007, 195(1):122-128.
14. Mora S., Glynn R.J., Ridker P.M. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 2013, 128(11):1189-1197.
15. Otvos J.D., Mora S., Shalaurova I., Greenland P., Mackey R.H., Goff D.C. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J. Clin. Lipidol. 2011, 5(2):105-113.
16. Mora S., Buring J.E., Ridker P.M. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation 2014, 129(5):553-561.
17. Mackey R.H., Kuller L.H., Sutton-Tyrrell K., Evans R.W., Holubkov R., Matthews K.A. Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study. Arch. Intern. Med. 2005, 165(5):510-515.
18. Chandra A., Neeland I.J., Das S.R., Khera A., Turer A.T., Ayers C.R., et al. Relation of black race between high density lipoprotein cholesterol content, high density lipoprotein particles and coronary events (from the Dallas Heart Study). Am. J. Cardiol. 2015, 115(7):890-894.
19. El Harchaoui K., van der Steeg W.A., Stroes E.S., Kuivenhoven J.A., Otvos J.D., Wareham N.J., et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J. Am. Coll. Cardiol. 2007, 49(5):547-553.
20. Mora S., Szklo M., Otvos J.D., Greenland P., Psaty B.M., Goff D.C., et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007, 192(1):211-217.
21. El Harchaoui K., Arsenault B.J., Franssen R., Despres J.P., Hovingh G.K., Stroes E.S., et al. High-density lipoprotein particle size and concentration and coronary risk. Ann. Intern. Med. 2009, 150(2):84-93.
22. van der Steeg W.A., Holme I., Boekholdt S.M., Larsen M.L., Lindahl C., Stroes E.S., et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol. 2008, 51(6):634-642.
23. Anderson G.L., Manson J., Wallace R., Lund B., Hall D., Davis S., et al. Implementation of the Women's Health Initiative study design. Ann. Epidemiol. 2003, 13(9 Suppl):S5-S17.
24. Barlow W.E., Ichikawa L., Rosner D., Izumi S. Analysis of case-cohort designs. J. Clin. Epidemiol. 1999, 52(12):1165-1172.
25. Curb J.D., McTiernan A., Heckbert S.R., Kooperberg C., Stanford J., Nevitt M., et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann. Epidemiol. 2003, 13(9 Suppl):S122-S128.
26. Go A.S., Bauman M.A., Coleman King S.M., Fonarow G.C., Lawrence W., Williams K.A., et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J. Am. Coll. Cardiol. 2014, 63(12):1230-1238.
27. American Diabetes A (2) Classification and diagnosis of diabetes. Diabetes Care 2015, 38(Suppl. (Supplement 1)):S8-S16.
28. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin. Lab. Med. 2006, 26(4):847-870.
29. Mackey R.H., Mora S., Bertoni A.G., Wassel C.L., Carnethon M.R., Sibley C.T., et al. Lipoprotein particles and incident type 2 diabetes in the Multi-ethnic Study of Atherosclerosis. Diabetes Care 2015, [Epub ahead of print].
30. Mora S., Otvos J.D., Rifai N., Rosenson R.S., Buring J.E., Ridker P.M. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 119(7):931-939.
31. Kontush A., Chapman M.J. Why is HDL functionally deficient in type 2 diabetes?. Curr. Diab. Rep. 2008, 8(1):51-59.
32. Camont L., Chapman M.J., Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol. Med. 2011, 17(10):594-603.
33. von Eynatten M., Hamann A., Twardella D., Nawroth P.P., Brenner H., Rothenbacher D. Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur. Heart J. 2008, 29(10):1307-1315.
34. Wannamethee S.G., Welsh P., Whincup P.H., Sawar N., Thomas M.C., Gudnarsson V., et al. High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association?. Eur. J. Cardiovasc. Prev. Rehabil. 2011, 18(1):65-71.
35. Kizer J.R., Benkeser D., Arnold A.M., Mukamal K.J., Ix J.H., Zieman S.J., et al. Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study. Circulation 2012, 126(25):2951-2961.
36. Kizer J.R., Benkeser D., Arnold A.M., Djousse L., Zieman S.J., Mukamal K.J., et al. Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults. J. Clin. Endocrinol. Metab. 2013, 98(1):255-263.
37. Tsukamoto O., Fujita M., Kato M., Yamazaki S., Asano Y., Ogai A., et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J. Am. Coll. Cardiol. 2009, 53(22):2070-2077.
38. Piemonti L., Calori G., Mercalli A., Lattuada G., Monti P., Garancini M.P., et al. Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care 2003, 26(10):2883-2889.
39. Allison M.A., Bluemke D.A., McClelland R., Cushman M., Criqui M.H., Polak J.F., et al. Relation of leptin to left ventricular hypertrophy (from the Multi-ethnic Study of Atherosclerosis). Am. J. Cardiol. 2013, 112(5):726-730.
40. Mackey R.H., Belle S.H., Courcoulas A.P., Dakin G.F., Deveney C.W., Flum D.R., et al. Distribution of 10-year and lifetime predicted risk for cardiovascular disease prior to surgery in the longitudinal assessment of bariatric surgery-2 study. Am. J. Cardiol. 2012, 60(6):508-516.
41. Davidson M.H., Ballantyne C.M., Jacobson T.A., Bittner V.A., Braun L.T., Brown A.S., et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J. Clin. Lipidol. 2011, 5(5):338-367.
42. McTigue K., Larson J.C., Valoski A., Burke G., Kotchen J., Lewis C.E., et al. Mortality and cardiac and vascular outcomes in extremely obese women. JAMA 2006, 296(1):79-86.
43. Livingston E.H., Chandalia M., Abate N. Do current body mass index criteria for obesity surgery reflect cardiovascular risk?. Surg. Obes. Relat. Dis. 2007, 3(6):577-585.
44. Matthews K.A., Crawford S.L., Chae C.U., Everson-Rose S.A., Sowers M.F., Sternfeld B., et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?. J. Am. Coll. Cardiol. 2009, 54(25):2366-2373.
45. Kuller L.H., Pettee Gabriel K.K., Kinzel L.S., Underwood D.A., Conroy M.B., Chang Y., et al. The Women on the Move Through Activity and Nutrition (WOMAN) study: final 48-month results. Obesity (Silver Spring) 2012, 20(3):636-643.
46. Rosenson R.S., Otvos J.D., Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care 2009, 32(6):1087-1091.
47. Mora S., Glynn R.J., Hsia J., MacFadyen J.G., Genest J., Ridker P.M. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010, 121(9):1069-1077.